Fenimore Christopher R. 的 Form 4 申報
Regeneron Pharmaceuticals, Inc.（REGN），2024/2/12 申報
- 申報編號
- 0001968202-24-000061
- 申報時間
- 2024/2/12
- 交易日
- 2024/2/9
- 申報延遲
- 3 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 6 筆非衍生性交易。公開市場賣出合計 $468.9 萬。交易後 3 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Fenimore Christopher R.CIK 0001697422 | 高階主管（SVP Finance & CFO） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2024/2/9 | Common Stock | S賣出處分 | −344 | $950.49F1 | −$326,968.56 | 18,947 | 直接 | |
| 2024/2/9 | Common Stock | S賣出處分 | −487 | $951.39F2 | −$463,326.93 | 18,460 | 直接 | |
| 2024/2/9 | Common Stock | S賣出處分 | −1,046 | $952.62F3 | −$996,440.52 | 17,414 | 直接 | |
| 2024/2/9 | Common Stock | S賣出處分 | −1,342 | $953.47F4 | −$1,279,556.74 | 16,072 | 直接 | |
| 2024/2/9 | Common Stock | S賣出處分 | −1,100 | $954.57F5 | −$1,050,027 | 14,972 | 直接 | |
| 2024/2/9 | Common Stock | S賣出處分 | −600 | $955.00 | −$573,000 | 14,372 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
Represents volume-weighted average price of sales of 344 shares of Company stock on February 9, 2024 at prices ranging from $950.33 to $950.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2024 at each separate price.
表 I 有 1 筆交易的價格引用這則附註。
- F2
Represents volume-weighted average price of sales of 487 shares of Company stock on February 9, 2024 at prices ranging from $951.03 to $951.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2024 at each separate price.
表 I 有 1 筆交易的價格引用這則附註。
- F3
Represents volume-weighted average price of sales of 1,046 shares of Company stock on February 9, 2024 at prices ranging from $952.11 to $952.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2024 at each separate price.
表 I 有 1 筆交易的價格引用這則附註。
- F4
Represents volume-weighted average price of sales of 1,342 shares of Company stock on February 9, 2024 at prices ranging from $953.02 to $953.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2024 at each separate price.
表 I 有 1 筆交易的價格引用這則附註。
- F5
Represents volume-weighted average price of sales of 1,100 shares of Company stock on February 9, 2024 at prices ranging from $954.00 to $954.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 9, 2024 at each separate price.
表 I 有 1 筆交易的價格引用這則附註。